Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 104129, 9 pages
http://dx.doi.org/10.1155/2014/104129
Research Article

Study of Microvessel Density and the Expression of Vascular Endothelial Growth Factors in Adrenal Gland Pheochromocytomas

1Department of Pathomorphology, Jagiellonian University Medical College (UJCM), Grzegórzecka Street 16, 31-531 Cracow, Poland
2Faculty of Physics and Applied Computer Science, AGH-University of Science and Technology, Aleja Mickiewicza 30, 30-059 Cracow, Poland
3Jagiellonian University Medical College, Kopernika Street 17, 31-501 Cracow, Poland
4II Department of General Surgery, Jagiellonian University Medical College, University Hospital, Kopernika 21 Street, 31-501 Cracow, Poland

Received 13 June 2014; Revised 15 August 2014; Accepted 18 August 2014; Published 3 September 2014

Academic Editor: Claudio Letizia

Copyright © 2014 Magdalena Białas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Miettinen, “Paragangiomas,” in Modern Soft Tissue Pathology—Tumors and Non-Neoplastic Conditions, M. Miettinen, Ed., pp. 755–774, Cambridge University Press, New York, NY, USA, 2010. View at Google Scholar
  2. E. E. Lack, “Tumors of the adrenal glands and extraadrenal paraganglia,” in AFIP Atlas of Tumor Pathology, ARP Press, Silver Spring, Md, USA, 2007. View at Google Scholar
  3. A. M. McNicol, “Update on tumours of the adrenal cortex, phaeochromocytoma and extra-adrenal paraganglioma,” Histopathology, vol. 58, no. 2, pp. 155–168, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. de Wailly, L. Oragano, F. Radé et al., “Malignant pheochromocytoma: new malignancy criteria,” Langenbeck's Archives of Surgery, vol. 397, no. 2, pp. 239–246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Agarwal, P. K. Mehrotra, M. Jain et al., “Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?” World Journal of Surgery, vol. 34, no. 12, pp. 3022–3028, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. DeLellis, R. V. Lloyd, P. U. Heitz, and C. Eng, Tumours of Endocrine Organs—Pathology and Genetics, WHO Classification of Tumours, IARC Press, Lyon, France, 2004.
  7. P.-F. Plouin, G. Chatellier, I. Fofol, and P. Corvol, “Tumor recurrence and hypertension persistence after successful pheochromocytoma operation,” Hypertension, vol. 29, no. 5, pp. 1133–1139, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Pacak, G. Eisenhofer, H. Ahlman et al., “Pheochromocytoma: Recommendations for clinical practice from the First International Symposium,” Nature Clinical Practice Endocrinology and Metabolism, vol. 3, no. 2, pp. 92–102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. L. D. R. Thompson, “Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases,” The American Journal of Surgical Pathology, vol. 26, no. 5, pp. 551–566, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Kumar, A. K. Abbas, N. Fausto et al., Robbins and Cotran Pathologic Basis of Disease, 8th edition, 2010.
  11. S. Sharma, M. C. Sharma, and C. Sarkar, “Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis,” Histopathology, vol. 46, no. 5, pp. 481–489, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. P. B. Vermeulen, G. Gasparini, S. B. Fox et al., “Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours,” European Journal of Cancer, vol. 38, no. 12, pp. 1564–1579, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Białas, K. Okoń, G. Dyduch et al., “Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas—a comparative study,” Polish Journal of Pathology, vol. 64, no. 2, pp. 129–135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Bergers and L. E. Benjamin, “Tumorigenesis and the angiogenic switch,” Nature Reviews Cancer, vol. 3, no. 6, pp. 401–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Ferrara, “VEGF and the quest for tumour angiogenesis factors,” Nature Reviews Cancer, vol. 2, no. 10, pp. 795–803, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Nyberg, L. Xie, and R. Kalluri, “Endogenous inhibitors of angiogenesis,” Cancer Research, vol. 65, no. 10, pp. 3967–3979, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Pallares, F. Rojo, J. Iriarte, J. Morote, L. I. Armadans, and I. de Torres, “Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues,” Histology and Histopathology, vol. 21, no. 8, pp. 857–865, 2006. View at Google Scholar · View at Scopus
  18. P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Fukumura, D. G. Duda, L. L. Munn, and R. K. Jain, “Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models,” Microcirculation, vol. 17, no. 3, pp. 206–225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Weidner, “Intratumor microvessel density as a prognostic factor in cancer,” American Journal of Pathology, vol. 147, no. 1, pp. 9–19, 1995. View at Google Scholar · View at Scopus
  21. J. Hasan, R. Byers, and G. C. Jayson, “Intra-tumoural microvessel density in human solid tumours,” British Journal of Cancer, vol. 86, no. 10, pp. 1566–1577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Favier, P. Igaz, N. Burnichon et al., “Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma,” Endocrine Pathology, vol. 23, no. 1, pp. 34–42, 2012. View at Publisher · View at Google Scholar
  23. Q. Liu, G. Djuricin, E. D. Staren et al., “Tumor angiogenesis in pheochromocytomas and paragangliomas,” Surgery, vol. 120, no. 6, pp. 938–942, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Favier, P.-F. Plouin, P. Corvol, and J.-M. Gasc, “Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors,” The American Journal of Pathology, vol. 161, no. 4, pp. 1235–1246, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Trojan, D. Thomas, D. Friedrich et al., “Expression of different vascular endothelial markers in prostate cancer and BPH tissue: an immunohistochemical and clinical evaluation,” Anticancer Research, vol. 24, no. 3, pp. 1651–1656, 2004. View at Google Scholar · View at Scopus
  26. Y. M. El-Gohary, J. F. Silverman, P. R. Olson et al., “Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma,” American Journal of Clinical Pathology, vol. 127, no. 4, pp. 572–579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Białas, K. Okoń, and J. Czopek, “Assessing microvessel density in gastric carcinoma: a comparison of three markers,” Polish Journal of Pathology, vol. 54, no. 4, pp. 249–252, 2003. View at Google Scholar · View at Scopus
  28. Y. Zhang, Y. Yang, H. Hong, and W. Cai, “Multimodality molecular imaging of CD105 (Endoglin) expression,” International Journal of Clinical and Experimental Medicine, vol. 4, no. 1, pp. 32–42, 2011. View at Google Scholar
  29. N. A. Dallas, S. Samuel, L. Xia et al., “Endoglin (CD105): a marker of tumor vasculature and potential target for therapy,” Clinical Cancer Research, vol. 14, no. 7, pp. 1931–1937, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Fonsatti, L. Sigalotti, P. Arslan, M. Altomonte, and M. Maio, “Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies,” Current Cancer Drug Targets, vol. 3, no. 6, pp. 427–432, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. J. M. Rubatt, K. M. Darcy, A. Hutson et al., “Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 112, no. 3, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Białas, G. Dyduch, J. Szpor, S. Demczuk, and K. Okoń, “Microvascular density and mast cells in benign and malignant pheochromocytomas,” Polish Journal of Pathology, vol. 63, no. 4, pp. 235–242, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. P. P. G. M. Rooijens, R. R. De Krijger, H. J. Bonjer et al., “The significance of angiogenesis in malignant pheochromocytomas,” Endocrine Pathology, vol. 15, no. 1, pp. 39–45, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Zielke, M. Middeke, S. Hoffmann et al., “VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors,” Surgery, vol. 132, no. 6, pp. 1056–1063, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Feng, Y. Zhu, X. Wang et al., “Predictive factors for malignant pheochromocytoma: analysis of 136 patients,” Journal of Urology, vol. 185, no. 5, pp. 1583–1589, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Kolomecki, H. Stepien, M. Bartos, and K. Kuzdak, “Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours,” Endocrine Regulations, vol. 35, no. 1, pp. 9–16, 2001. View at Google Scholar · View at Scopus
  37. K. Takekoshi, K. Isobe, T. Yashiro et al., “Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas,” Life Sciences, vol. 74, no. 7, pp. 863–871, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Ohji, O. Iciyanagi, Y. Suzuki, T. Nakada, and I. Sasagawa, “Tumour angiogenesis and Ki-67 expression in phaeochromocytoma,” BJU International, vol. 87, no. 4, pp. 381–385, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B. Grossman, “The diagnosis and management of malignant phaeochromocytoma and paraganglioma,” Endocrine-Related Cancer, vol. 14, no. 3, pp. 569–585, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Ayala-Ramirez, C. N. Chougnet, M. A. Habra et al., “Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 11, pp. 4040–4050, 2012. View at Publisher · View at Google Scholar · View at Scopus